InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

March 26, 2024

https://www.globenewswire.com/news-release/2024/03/26/2852210/0/en/InspireMD-Announces-Abstract-of-One-Year-Follow-Up-Results-from-the-C-GUARDIANS-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial-Accepted-for-Presentation-at-LINC-2024.html

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.